The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex

Coot : model-building tools for molecular graphics

Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571

Phaser crystallographic software

McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612

Refinement of Macromolecular Structures by the Maximum-Likelihood Method

Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,796

Epigenetic Regulations of GABAergic Neurotransmission: Relevance for Neurological Disorders and Epigenetic Therapy

Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,951

Selective inhibition of BET bromodomains

Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262

A gene complex controlling segmentation in Drosophila

Lewis, E. B. (1978) · Nature · doi:10.1038/276565a0 · Cited by 3,813

Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions

Krissinel, E., & Henrick, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904026460 · Cited by 3,788

Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing

Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775

The Polycomb complex PRC2 and its mark in life

Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347

The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability

Niesen, F., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,420

Identification of a cytisine-based EED-EZH2 protein-protein interaction inhibitor preventing metastasis in triple-negative breast cancer cells

Cheng, S., Yang, G., Wang, W., Song, Y., Ko, C.-N., Han, Q., Ma, D., & Leung, C. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-0006 · Cited by 22

Telomere dysfunction cooperates with epigenetic alterations to impair murine embryonic stem cell fate commitment

Criqui, M., Qamra, A., Chu, T. W., Sharma, M., Tsao, J., Henry, D., Baršytė-Lovejoy, D., Arrowsmith, C. H., Winegarden, N. A., Lupien, M., et al. (2020) · eLife · doi:10.7554/elife.47333 · Cited by 22

Colon cancer stemness as a reversible epigenetic state: Implications for anticancer therapies

Vincent, A., Ouelkdite, A., Souidi, M., Leclerc, J., Neve, B., & SEUNINGEN, I. V. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i11.920 · Cited by 23

Systematic Variation of Both the Aromatic Cage and Dialkyllysine via GCE-SAR Reveal Mechanistic Insights in CBX5 Reader Protein Binding

Kean, K. M., Baril, S. A., Lamb, K. N., Dishman, S. N., Treacy, J. W., Houk, K. N., Brustad, E. M., James, L. I., & Waters, M. L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02049 · Cited by 20

Focus on the classical and non-classical functions of EZH2: Guide the development of inhibitors and degraders

Zhang, Q., Yang, H., Feng, Q., Cao, J., Zhang, Y., Li, L., & Yu, L. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106159 · Cited by 20

Exposure to high-sugar diet induces transgenerational changes in sweet sensitivity and feeding behavior via H3K27me3 reprogramming

Yang, J., Tang, R., Chen, S., Chen, Y., Zhang, L., Yuan, K., Huang, R., & Wang, L. (2023) · eLife · doi:10.7554/elife.85365 · Cited by 22

Targeting lysine specific demethylase 4A (KDM4A) tandem TUDOR domain – A fragment based approach

Upadhyay, A. K., Judge, R. A., Li, L., Pithawalla, R. B., Simanis, J. A., Bodelle, P. M., Marin, V. L., Henry, R. F., Petros, A. M., & Sun, C. C. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.04.050 · Cited by 20

Novel therapeutic strategies for MLL-rearranged leukemias

Wong, N.-H. M., & So, C. W. E. (2020) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2020.194584 · Cited by 20

Alterations of Histone Modifications in Cancer

Hosseini, A., & Minucci, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812215-0.00006-6 · Cited by 22

Drug addiction unveils a repressive methylation ceiling in EZH2-mutant lymphoma

Kwok, H. S., Freedy, A. M., Siegenfeld, A. P., Morriss, J. W., Waterbury, A. L., Kissler, S. M., & Liau, B. B. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01299-1 · Cited by 21

Polycomb and Trithorax Group Proteins: The Long Road from Mutations in Drosophila to Use in Medicine

Chetverina, D., Ломаев, Д. В., & Erokhin, M. (2020) · Acta Naturae · doi:10.32607/actanaturae.11090 · Cited by 18

Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase

O’Donovan, D. H., Gregson, C. L., Packer, M. J., Greenwood, R. D. R., Pike, K. G., Kawatkar, S. P., Bloecher, A., Robinson, J. D., Read, J. A., Code, E. L., et al. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127904 · Cited by 20

Critical Roles of Polycomb Repressive Complexes in Transcription and Cancer

Dong, G., Xu, J., Qi, Y.-R., Yuan, Z., & Zhao, W. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179574 · Cited by 21

Structure-Based Design of the Indole-Substituted Triazolopyrimidines as New EED–H3K27me3 Inhibitors for the Treatment of Lymphoma

Dong, G., Zuo, J.-H., Yu, J., Xu, J., Gao, G., Li, G., Zhao, W. H., & Yu, B. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02028 · Cited by 21

Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs

Zhao, Y., Guan, Y., Zhao, F., Yu, T., Zhang, S., Zhang, Y., Duan, Y., & Zhou, X. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114144 · Cited by 19

Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomas

Lanzi, C., & Cassinelli, G. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114944 · Cited by 18

Small molecule and peptide inhibitors of βTrCP and the βTrCP–NRF2 protein–protein interaction

Jaffry, U., & Wells, G. (2023) · Biochemical Society Transactions · doi:10.1042/bst20220352 · Cited by 18

Perspectives on current approaches to virtual screening in drug discovery

Muegge, I., Bentzien, J., & Ge, Y. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2390511 · Cited by 20

Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED–EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations

Zhu, K., Du, D., Yang, R. J., Tao, H., & Zhang, H. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00550 · Cited by 18

Identification and characterization of second-generation EZH2 inhibitors with extended residence times and improved biological activity

Stuckey, J. I., Cantone, N. R., Côté, A., Arora, S., Vivat, V., Ramakrishnan, A., Mertz, J. A., Khanna, A., Brenneman, J. B., Gehling, V. S., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100349 · Cited by 18

Small molecule therapeutics to treat the β-globinopathies

Yu, L., Myers, G., & Engel, J. D. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000579 · Cited by 15

Recent progress on small molecules targeting epigenetic complexes

Itoh, Y., Takada, Y., Yamashita, Y., & Suzuki, T. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102130 · Cited by 16

Approaching the catalytic mechanism of protein lysine methyltransferases by biochemical and simulation techniques

Schnee, P., Pleiss, J., & Jeltsch, A. (2024) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2024.2318547 · Cited by 18

Discovery of a novel 53BP1 inhibitor through AlphaScreen-based high-throughput screening

Sun, Y., Lu, H., Fang, X., Xiao, S.-H., Yang, F., Chen, Y., Wang, H., Li, X., Lu, J., Lin, H., et al. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116054 · Cited by 16

A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies

Ribrag, V., Iglesias, L., de Braud, F., Ma, B. B. Y., Yokota, T., Zander, T., Spreafico, A., Subbiah, V., Illert, A. L., Tan, D., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115122 · Cited by 15

Polycomb repressive complex 2 inhibitors: emerging epigenetic modulators

Danishuddin, M., Subbarao, N., Faheem, M., & Khan, S. N. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.07.002 · Cited by 15

A Solid‐Phase Approach to Accessing Bisthioether‐Stapled Peptides Resulting in a Potent Inhibitor of PRC2 Catalytic Activity

Zhang, G., Barragán, F., Wilson, K., Levy, N., Herskovits, A., Sapozhnikov, M., Rodrı́guez, Y., Kelmendi, L., Alkasimi, H., Korsmo, H. W., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201810007 · Cited by 16

Discovery of selective activators of PRC2 mutant EED-I363M

Suh, J. L., Barnash, K. D., Abramyan, T. M., Li, F., The, J., Engelberg, I. A., Vedadi, M., Brown, P. J., Kireev, D., Arrowsmith, C. H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43005-z · Cited by 15

Know when to fold ‘em: Polycomb complexes in oncogenic 3D genome regulation

Doyle, E. J., Morey, L., & Conway, E. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.986319 · Cited by 16

A conserved switch to less catalytically active Polycomb repressive complexes in non-dividing cells

McCole, R., Nolan, J., Reck, D. M., Monger, C., Rustichelli, S., Conway, E., Brien, G. L., Wang, C., Deevy, O., Neikes, H. K., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2024.115192 · Cited by 13

Transcriptome-Wide Identification of Coding and Noncoding RNA-Binding Proteins Defines the Comprehensive RNA Interactome of Leishmania mexicana

Kalesh, K., Wei, W., Mantilla, B. S., Roumeliotis, T. I., Choudhary, J. S., & Denny, P. W. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02422-21 · Cited by 14

Are We There Yet? Applying Thermodynamic and Kinetic Profiling on Embryonic Ectoderm Development (EED) Hit-to-Lead Program

Wang, Y., Edalji, R. P., Panchal, S. C., Sun, C. C., Djurić, S. W., & Vasudevan, A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00576 · Cited by 14

Binding Modes of Small‐Molecule Inhibitors to the EED Pocket of PRC2

Huang, D., Tian, S., Qi, Y., & Zhang, J. Z. H. (2019) · ChemPhysChem · doi:10.1002/cphc.201900903 · Cited by 14

UTP18-mediated p21 mRNA instability drives adenoma-carcinoma progression in colorectal cancer

Pan, M., Xiao, T., Xu, L., Xie, Y., & Ge, W. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112423 · Cited by 14

A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention

Svrlanska, A., Reichel, A., Schilling, E.-M., Scherer, M., Stamminger, T., & Reuter, N. (2019) · Journal of Virology · doi:10.1128/jvi.02143-18 · Cited by 16

An update on allosteric modulators as a promising strategy targeting histone methyltransferase

Tan, Z., Li, T., Lei, H., & Zhai, X. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105865 · Cited by 12

Combinatorial Anticancer Drug Screen Identifies Off-Target Effects of Epigenetic Chemical Probes

Barghout, S. H., Mann, M. K., Aman, A. M., Yu, Y., Alteen, M. G., Schimmer, A. D., Schapira, M., Arrowsmith, C. H., & Baršytė-Lovejoy, D. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00451 · Cited by 12

Pharmacological Modulation of Transcriptional Coregulators in Cancer

Bishop, T. R., Zhang, Y., & Erb, M. A. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.04.004 · Cited by 11

Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED)

Yang, C., & Wang, S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00287 · Cited by 12

Domain cross-talk in regulation of histone modifications: Molecular mechanisms and targeting opportunities

Longbotham, J. E., Zhang, M. Y., & Fujimori, D. G. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.06.001 · Cited by 12

Chemical Genetics Screen Identifies COPB2 Tool Compounds That Alters ER Stress Response and Induces RTK Dysregulation in Lung Cancer Cells

Saraon, P., Snider, J. D., Schormann, W., Rai, A., Radulovich, N., Sánchez‐Osuna, M., Coulombe‐Huntington, J., Huard, C., Mohammed, M., Lima‐Fernandes, E., et al. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167294 · Cited by 10

A Structural Perspective on Gene Repression by Polycomb Repressive Complex 2

Liu, X. (2020) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-58971-4_17 · Cited by 11

Gene-repressing epigenetic reader EED unexpectedly enhances cyclinD1 gene activation

Zhang, M., Li, J., Wang, Q., Urabe, G., Tang, R., Huang, Y., Mosquera, J. V., Kent, K. C., Wang, B., Miller, C. L., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.02.024 · Cited by 10

An evolving landscape of PRC2–RNA interactions in chromatin regulation

Aguilar, R., Rosenberg, M., Levy, V., & Lee, J. T. (2025) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-025-00850-3 · Cited by 12

Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models

Li, X., Chen, Y., Bai, L., Zhao, R., Wu, Y., Xie, Z., Wu, J. M., Bowen, N. J., Danaher, A., Cook, N., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02359-y · Cited by 9

Exploring the therapeutic potential of targeting polycomb repressive complex 2 in lung cancer

Gao, M., Li, Y., Cao, P., Liu, H., Chen, J., & Kang, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1216289 · Cited by 12

Rational Adaptation of L3MBTL1 Inhibitors to Create Small‐Molecule Cbx7 Antagonists

Simhadri, C., Daze, K. D., Douglas, S. F., Milosevich, N., Monjas, L., Dev, A., Brown, T. M., Hirsch, A. K. H., Wulff, J. E., & Hof, F. A. (2019) · ChemMedChem · doi:10.1002/cmdc.201900021 · Cited by 9

Methyl-Readers and Inhibitors

Sbardella, G. (2019) · Topics in medicinal chemistry · doi:10.1007/7355_2019_78 · Cited by 9

Identification of catalytic and non‐catalytic activity inhibitors against PRC2‐EZH2 complex through multiple high‐throughput screening campaigns

Zhou, Y., Du, D., Wang, J., Cai, X., Deng, A. X., Nosjean, O., Boutin, J. A., Renard, P., Yang, D., Luo, C., et al. (2020) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13702 · Cited by 9

DOT1L interaction partner AF10 controls patterning of H3K79 methylation and RNA polymerase II to maintain cell identity

Wille, C. K., Neumann, E. N., Deshpande, A. J., & Sridharan, R. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.10.017 · Cited by 10

Allosteric regulation of histone lysine methyltransferases: from context-specific regulation to selective drugs

Davidovich, C., & Zhang, Q. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200238 · Cited by 9

The PRC2 molecule EED is a target of epigenetic therapy for neuroblastoma

Shaliman, D., Takenobu, H., Sugino, R. P., Ohira, M., & Kamijo, T. (2022) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2022.151238 · Cited by 8

SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters

Groß, E., Hilger, R. A., Schümann, F. L., Bauer, M., Bouska, A. C., Rohde, C., Willscher, E., Lützkendorf, J., Müller, L. P., Edemir, B., et al. (2023) · Cancers · doi:10.3390/cancers15113043 · Cited by 8

Therapeutic targeting potential of chromatin-associated proteins in MLL-rearranged acute leukemia

Xu, X., & Schneider, B. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0414-4 · Cited by 8

The Contribution of the Zebrafish Model to the Understanding of Polycomb Repression in Vertebrates

Hanot, M., Raby, L., Völkel, P., Bourhis, X. L., & Angrand, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032322 · Cited by 10

A miniaturized mode-of-action profiling platform enables high throughput characterization of the molecular and cellular dynamics of EZH2 inhibition

Falkenstern, L., Georgi, V., Bunse, S., Badock, V., Husemann, M., Roehn, U., Stellfeld, T., Fitzgerald, M. E., Ferrara, S. J., Stöckigt, D., et al. (2024) · Scientific Reports · doi:10.1038/s41598-023-50964-x · Cited by 8

Pharmacological Advancements of PRC2 in Cancer Therapy: A Narrative Review

Wang, M. S., Sussman, J., Xu, J.-J., Patel, R. T., Elghawy, O., & Rawla, P. (2024) · Life · doi:10.3390/life14121645 · Cited by 7

Exploiting binding-site arginines in drug design: Recent examples

Lin, H., & Luengo, J. I. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127442 · Cited by 8

Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method

Misawa, K., Yamaotsu, N., & Hirono, S. (2021) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-021-00378-6 · Cited by 7

Technical aspects of megaureter repair.

Hendren, W. H. (1977) · PubMed · Cited by 7

Erratum: The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex

He, Y., Selvaraju, S., Curtin, M. L., Jakob, C. G., Zhu, H., Comess, K. M., Shaw, B., The, J., Lima‐Fernandes, E., Szewczyk, M. M., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio0817-922b · Cited by 7

Ceramide turnover (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

Futerman, A. H. (2019) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f767/2019.4 · Cited by 6

Dual-Acting Peptides Target EZH2 and AR: A New Paradigm for Effective Treatment of Castration-Resistant Prostate Cancer

Han, Z., Rimal, U., Khatiwada, P., Brandman, J., Zhou, J., Hussain, M. S., Viola, R. E., & Shemshedini, L. (2022) · Endocrinology · doi:10.1210/endocr/bqac180 · Cited by 6

Polycomb Assemblies Multitask to Regulate Transcription

Vidal, M. (2019) · Epigenomes · doi:10.3390/epigenomes3020012 · Cited by 8

Ceramide turnover (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database

Futerman, A. H. (2020) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f767/2020.5 · Cited by 6

Genetic Impairments of PRC2 Activity in Oncology: Problems and Prospects

Chetverina, D., Ломаев, Д. В., Georgiev, P. G., & Erokhin, M. (2021) · Russian Journal of Genetics · doi:10.1134/s1022795421030042 · Cited by 5

Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations

Alqazzaz, M., Luciani, G. M., Vu, V., Machado, R. A. C., Szewczyk, M. M., Adamson, E. C., Cheon, S., Li, F., Arrowsmith, C. H., Minden, M. D., et al. (2023) · Experimental Hematology · doi:10.1016/j.exphem.2023.11.009 · Cited by 5

Peptide Technologies in the Development of Chemical Tools for Chromatin‐Associated Machinery

Barnash, K. D., Lamb, K. N., James, L. I., & Frye, S. V. (2017) · Drug Development Research · doi:10.1002/ddr.21398 · Cited by 5

CRISPR ‐Cas9 screen reveals that inhibition of enhancer of zeste homolog 2 sensitizes malignant T cells to dimethyl‐fumarate‐induced cell death

Teubner, J.-P., Tümen, D., Kandulski, A., Heumann, P., Mester, P., Aschenbrenner, E., Pollinger, K., Gunckel, M., Volz, B., Hein, T., et al. (2025) · FEBS Journal · doi:10.1111/febs.70208 · Cited by 4

WDR54 exerts oncogenic roles in T‐cell acute lymphoblastic leukemia

Li, H., Zhang, D., Fu, Q., Wang, S., Zhang, X., Lin, Z., Wang, Z., Song, J., Su, Z., Xue, V. W., et al. (2023) · Cancer Science · doi:10.1111/cas.15872 · Cited by 3

CDC40 suppression induces CDCA5 splicing defects and anti-proliferative effects in lung cancer cells

Hu, D., Thériault, B. L., Talebian, V., Hoffer, L., Owen, J., Lim, J., Blencowe, B. J., Lima‐Fernandes, E., Saraon, P., Marcellus, R. C., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-83337-z · Cited by 4

Inhibition of EED-mediated histone methylation alleviates neuroinflammation by suppressing WNT-mediated dendritic cell migration

Hong, W., Ma, H., Li, Z., Du, Y., Xia, W., Yin, H., Huang, H., Sun, Z., Gai, R., Tong, L., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03429-z · Cited by 4

Allosteric histone methyltransferase modulators block tumour growth

Crunkhorn, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.28 · Cited by 3

Histone methylation modifiers in medical therapeutics

Trojer, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00020-7 · Cited by 3

Breaking into the PRC2 cage

Holoch, D., & Margueron, R. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2313 · Cited by 3

Recent Advances in Chemical Tools for the Regulation and Study of Protein Lysine Methyltransferases

Hirano, T., Mori, S., & Kagechika, H. (2018) · The Chemical Record · doi:10.1002/tcr.201800034 · Cited by 3

Chromatin Regulatory Targets for Anticancer Therapeutics

Barta, P. A., Carter, T. R., & Erb, M. A. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00231 · Cited by 2

Structural landscape of H3K27me3 recognition by protein domains and their potential for inhibition

Rosas, R., Baracaldo-Lancheros, L. F., Dykhuizen, E. C., & Musselman, C. A. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.111344 · Cited by 2

Small Molecule Inhibitors Targeting New Targets of Protein-Protein Interactions

Yue, L., Wan, W., Xu, P., Li, L., Wang, C., Zhang, Y., Xu, H., Zhang, R., Hu, J., Lu, W., et al. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_7 · Cited by 2

Mimicking the Nucleosomal Context in Peptide-Based Binders of a H3K36me Reader Increases Binding Affinity While Altering the Binding Mode

Horn, V., Jongkees, S. A. K., & van Ingen, H. (2020) · Molecules · doi:10.3390/molecules25214951 · Cited by 2

Fighting PRC1 via the RING

Plotnik, J. P. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00819-1 · Cited by 2

ProxyBind: A compendium of binding sites for proximity-induced pharmacology

Rovers, E., Liu, L., & Schapira, M. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.11.010 · Cited by 3

Polycomb Repressive Complex 2 in Oncology

Guo, Y., Yu, Y., & Wang, G. G. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-45654-1_9 · Cited by 2

A Solid‐Phase Approach to Accessing Bisthioether‐Stapled Peptides Resulting in a Potent Inhibitor of PRC2 Catalytic Activity

Zhang, G., Barragán, F., Wilson, K., Levy, N., Herskovits, A., Sapozhnikov, M., Rodrı́guez, Y., Kelmendi, L., Alkasimi, H., Korsmo, H. W., et al. (2018) · Angewandte Chemie · doi:10.1002/ange.201810007 · Cited by 2

The First CACHE Challenge – Identifying Binders of the WD-Repeat Domain of Leucine-Rich Repeat Kinase 2Preprint

Patrascu, M. B., Nivedha, A. K., Rostaing, O., Chukka, P., Moitessier, N., & Pottel, J. (2022) · ChemRxiv · doi:10.26434/chemrxiv-2022-ncqsj · Cited by 2

Identification of SET/EED Dual Binders As Innovative PRC2 Inhibitors

Catalano, R., Maruca, A., Rocca, R., Tassone, P., Panzarella, G., Costa, G., Ortuso, F., & Alcaro, S. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0010 · Cited by 1

Progress Toward Epigenetic Targeted Therapies for Childhood Cancer

Liapodimitri, A., Tetens, A. R., Craig-Schwartz, J., Lunsford, K., Skalitzky, K. O., & Koldobskiy, M. A. (2024) · Cancers · doi:10.3390/cancers16244149 · Cited by 2

Oncogenic and immunomodulatory functions of SUV420H1 in HPV-negative head and neck squamous cell carcinoma

Moshiri, A., Luff, M. K., Kim, S., Jiang, M., Dar, M. S., Patel, M., McKinnon, K., Edmondson, E. F., Bassel, L., Warner, A. C., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-09236-5 · Cited by 1

Epigenetic therapies—update on lysine methyltransferase/PRC complex inhibitors

Kim, S., Barkey, N. M., Atasoylu, O., & Dhanak, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91367-6.00011-8 · Cited by 1

Recent Developments in the Structural Mechanism of Protein Methyltransferase Inhibition

Leung, R., & Schapira, M. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-00084 · Cited by 1

Histone Methylation Modifiers in Medical Therapeutics

Trojer, P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00037-5 · Cited by 1

Polycomb Repressive Complex 2: Modulator Development for Functional Regulation of a Multiprotein Complex by Using Structural Information

Tokodai, Y., & Yakushiji, F. (2019) · ChemBioChem · doi:10.1002/cbic.201900212 · Cited by 1

Epigenetic Proteins as Emerging Drug Targets

Boriack‐Sjodin, P. A. (2020) · Wiley eBooks · doi:10.1002/9781118681121.ch18 · Cited by 1

The First CACHE Challenge – Identifying Binders of the WD-Repeat Domain of Leucine-Rich Repeat Kinase 2Preprint

Patrascu, M. B., Nivedha, A. K., Rostaing, O., Chukka, P., Moitessier, N., & Pottel, J. (2022) · ChemRxiv · doi:10.26434/chemrxiv-2022-ncqsj-v2 · Cited by 1

Recent novel tumor gatekeepers and potential therapeutic approaches (2017)

Zahid, K. R., Zada, H. K., Wassan, G. M., Hassan, W., Liu, K., Liu, Y., Liu, J., Zhao, H., & Qi, C. (2017) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v16i10.31

Epigenetic Vulnerabilities in Triple-Negative Breast Cancer

Kao, Y. I. (2017) · TSpace (University of Toronto)

Lysine Reader Proteins

Bacher, J., Robaa, D., Luise, C., Sippl, W., & Jung, M. (2019) · Methods and principles in medicinal chemistry · doi:10.1002/9783527809257.ch14

Lysine Methyltransferases and Their Inhibitors

Stazi, G., Zwergel, C., & Valente, S. (2019) · Topics in medicinal chemistry · doi:10.1007/7355_2019_72

Ceramide turnover in GtoPdb v.2021.3

Futerman, A. H. (2021) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f767/2021.3

Structure-Based Survey of the Human Proteome for Opportunities in Proximity PharmacologyPreprint

Rovers, E., & Schapira, M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.13.475779

Targeting the EED–H3K27me3 Interaction Allosterically Inhibits PRC2

(2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2017-030 · Cited by 2

Binding Modes of Small‐Molecule Inhibitors to the EED Pocket of PRC2

Huang, D., Tian, S., Qi, Y., & Zhang, J. Z. H. (2019) · ChemPhysChem · doi:10.1002/cphc.201900903 · Cited by 14

An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED

Qi, W., Zhao, K., Gu, J., Huang, Y., Wang, Y., Zhang, H., Zhang, M., Zhang, J., Yu, Z., Li, L., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2304 · Cited by 316

Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED

Li, L., Zhang, H., Zhang, M., Zhao, M., Feng, L., Luo, X., Gao, Z., Huang, Y. R., Ardayfio, O., Zhang, J.-H., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169855 · Cited by 54

Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED)

Yang, C., & Wang, S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00287 · Cited by 12